tiprankstipranks
Advertisement
Advertisement
Corcept Faces Investor Suit Over Relacorilant NDA Disclosure 
PremiumClass ActionCorcept Faces Investor Suit Over Relacorilant NDA Disclosure 
22d ago
Corcept Therapeutics price target raised to $110 from $100 at Canaccord
Premium
The Fly
Corcept Therapeutics price target raised to $110 from $100 at Canaccord
22d ago
Premium
Company Announcements
Corcept Wins FDA Approval for Lifyorli Ovarian Cancer Therapy
22d ago
Corcept Therapeutics management to meet with Piper Sandler
PremiumThe FlyCorcept Therapeutics management to meet with Piper Sandler
24d ago
Corcept Therapeutics director buys $3.3M in common stock
Premium
The Fly
Corcept Therapeutics director buys $3.3M in common stock
28d ago
Corcept Therapeutics Lawsuit: CORT Investors Face Losses After FDA Rejection and Alleged Misleading Statements
Premium
Class Action
Corcept Therapeutics Lawsuit: CORT Investors Face Losses After FDA Rejection and Alleged Misleading Statements
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100